Davis BM - Search Results

1

Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients.

Davis BM, Reese JS, Lingas K, Gerson SL. Davis BM, et al. J Hematother Stem Cell Res. 2003 Aug;12(4):375-87. doi: 10.1089/152581603322286015. J Hematother Stem Cell Res. 2003. PMID: 12965075

2

Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.

Liu L, Schwartz S, Davis BM, Gerson SL. Liu L, et al. Among authors: davis bm. Cancer Res. 2002 Jun 1;62(11):3070-6. Cancer Res. 2002. PMID: 12036916

3

Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.

Fontes AM, Davis BM, Encell LP, Lingas K, Covas DT, Zago MA, Loeb LA, Pegg AE, Gerson SL. Fontes AM, et al. Among authors: davis bm. Mol Cancer Ther. 2006 Jan;5(1):121-8. doi: 10.1158/1535-7163.MCT-05-0236. Mol Cancer Ther. 2006. PMID: 16432170

4

Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance.

Koç ON, Allay JA, Lee K, Davis BM, Reese JS, Gerson SL. Koç ON, et al. Among authors: davis bm. Semin Oncol. 1996 Feb;23(1):46-65. Semin Oncol. 1996. PMID: 8607032 Review.

5

Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.

Davis BM, Reese JS, Koç ON, Lee K, Schupp JE, Gerson SL. Davis BM, et al. Cancer Res. 1997 Nov 15;57(22):5093-9. Cancer Res. 1997. PMID: 9371508

6

Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.

Reese JS, Davis BM, Liu L, Gerson SL. Reese JS, et al. Among authors: davis bm. Clin Cancer Res. 1999 Jan;5(1):163-9. Clin Cancer Res. 1999. PMID: 9918215

7

DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.

Koç ON, Reese JS, Davis BM, Liu L, Majczenko KJ, Gerson SL. Koç ON, et al. Among authors: davis bm. Hum Gene Ther. 1999 Apr 10;10(6):1021-30. doi: 10.1089/10430349950018418. Hum Gene Ther. 1999. PMID: 10223735

8

Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.

Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL. Davis BM, et al. Hum Gene Ther. 1999 Nov 20;10(17):2769-78. doi: 10.1089/10430349950016500. Hum Gene Ther. 1999. PMID: 10584923

9

Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection.

Davis BM, Koç ON, Gerson SL. Davis BM, et al. Blood. 2000 May 15;95(10):3078-84. Blood. 2000. PMID: 10807772 Free article.

10

O6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents.

Davis BM, Koç ON, Reese JS, Gerson SL. Davis BM, et al. Prog Exp Tumor Res. 1999;36:65-81. doi: 10.1159/000061986. Prog Exp Tumor Res. 1999. PMID: 10386065 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

406 results

Search Page

Filters